Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau.
Neuropsychopharmacology
; 46(1): 98-115, 2021 01.
Article
in En
| MEDLINE
| ID: mdl-32898852
ABSTRACT
The repeated failures of amyloid-targeting therapies have challenged our narrow understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging investigations into the underlying mechanisms of disease. Increasing evidence indicates that AD develops from an intricate web of biochemical and cellular processes that extend far beyond amyloid and tau accumulation. This growing recognition surrounding the diversity of AD pathophysiology underscores the need for holistic systems-based approaches to explore AD pathogenesis. Here we describe how network-based proteomics has emerged as a powerful tool and how its application to the AD brain has provided an informative framework for the complex protein pathophysiology underlying the disease. Furthermore, we outline how the AD brain network proteome can be leveraged to advance additional scientific and translational efforts, including the discovery of novel protein biomarkers of disease.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Alzheimer Disease
Limits:
Humans
Language:
En
Journal:
Neuropsychopharmacology
Journal subject:
NEUROLOGIA
/
PSICOFARMACOLOGIA
Year:
2021
Document type:
Article
Affiliation country: